Lassen Therapeutics is a company that develops antibodies as potential treatments for fibrosis, rare diseases, and oncology. Its lead candidate is LASN01, a monoclonal antibody targeting IL-11 receptor alpha (IL-11R). IL-11 is also a pivotal effector of tumor microenvironment organization and tumor growth, playing a key role as a mediator between cancer and stromal cells.